• en
  • it
  • de
  • UPDATE: Supply situation in view of the current COVID-19 outbreak

    PharmaZell Group is very conscious of our important role and duty in delivering APIs to our customers and being an active part in maintaining the health system running.

    We have received feedbacks from the competent authorities that all our API manufacturing units in Raubling (Germany), Gropello (Italy), Chennai (India) and Vizag (India) have been considered critical for the health system and can continue to operate despite of various lock down orders affecting various other industries. The PharmaZell Group is committed to providing a safe and healthy working environment for our employees. We follow the official COVID-19 recommendations and are fully complying with the regulation issued by the competent local authorities.

    So far, we could limit the negative impact of disruptions of raw material supplies from China to a minimum. We monitor the situation very carefully, have used safety stocks and alternative, qualified vendors where appropriate. We also have been able to maintain our producing units to operate at satisfactory levels despite of the many operational challenges, namely in Northern Italy.

    We would like our customers to not request earlier shipments of already placed and confirmed orders. By doing so, larger disruption of supply chains and unnecessary stockpiling can be avoided for the larger benefit of all.

    Please feel free to contact your responsible account manager for more detailed product specific information.

    March 24th 2020

    ——————————————————————————————————————————

    To Whom it may concern

    The Corona Virus outbreak has triggered a number of emergency measures across China, though the Epicenter is only in the Wuhan / Hubei region. Due to this, most parts of China have extended holidays till Feb. 10th, 2020, some places even until Feb. 16th, 2020 as a precautionary measure.

    Due to this we expect some delays for our supplies from China, mainly due to port congestions, terminal closures and other delays because of lacking manpower.

    Such delays will not affect our production and ability to supply our end products, provided the outbreak control mechanisms do not lead into further closures or long lasting delays. We are closely monitoring the situation and are in contact with our suppliers in China. Right now we have no indications of further delays.

    Please be also assured that we have multi locational approved sources other than from China origin for our key raw and starting materials. Even here we are in touch with our suppliers in order to permanently check whether our sources outside of China face and issues in their supply chain.

    In case of any changes or supply issues due to further unexpected measures in China we will proactively inform you.

    Kind Regards,

    Global Supply Chain-Team

    10-Feb-2020

    More News and Fairs

    Breaking News: PharmaZell Group acquired by Bridgepoint

    The PharmaZell Group management is very pleased to inform that the Group was acquired by Bridgepoint from DPE Deutsche Private Equity and Maxburg Capital Partners for an undisclosed sum. Bridgepoint

    FarmaBios activities are regularly proceeding…

    During this critical and challenging period, Farmabios SpA states that our activities are regularly proceeding. We are conscious of the role and duty in delivering APIs, and our active part

    UPDATE: Supply situation in view of the current COVID-19 outbreak

    PharmaZell Group is very conscious of our important role and duty in delivering APIs to our customers and being an active part in maintaining the health system running. We have

    Farmabios Breaks Ground to Expand its Manufacturing Footprint in Gropello Cairoli (Italy)

    As part of an ongoing investment program to enhance PharmaZell Group’s production output, we have initiated the construction of a brand new large steroid building and a new warehouse on

    Renewed GMP Certificate for our Manufacturing Facility Farmabios in Gropello Cairoli (Italy)

    We are very glad to announce that the competent Italian authority (AIFA) has issued a renewed GMP certificate for our Farmabios SpA production facility [http://eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.do].

    Farmabios expands its portfolio with Cannabidiol API

    Global API supplier Farmabios announced today the addition of an ultra-pure synthetic Cannabidiol (CBD) drug substance to its portfolio. With an EU Drug Master File and cGMP manufacturing capacities, Farmabios